PURPOSE - Current European Association of Urology guidelines state that a PSA≥100 ng/ml at diagnosis indicates metastatic disease. The aim of the present study was to examine the association between PSA values ≥100 ng/ml at diagnosis, distant metastasis and prostate cancer-specific survival.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS - 15,635 men with prostate cancer diagnosed between 1998 and 2009 identified in the Prostate Cancer Data Base Sweden (PCBaSe) were included in a population-based register study. Prostate cancer-specific survival was compared between three groups: 1,879 men with PSA ≥100 ng/ml and negative imaging investigations (M0); 5,642 men with distant metastases on imaging (M1) and PSA ≥ 100 ng/ml, and 3,828 men with M1 and PSA < 100 ng/ml. A fourth group consisted of 4,286 men with PSA ≥ 100 ng/ml who had not undergone imaging (Mx), but were not included in the assessment of survival.
RESULTS - Of 7,521 men with PSA≥100 ng/ml undergoing imaging for staging, 26% were classified as M1. Only 59% of 3,527 men with PSA 100-300mg/ml had distant metastases on imaging. The 5-year prostate cancer-specific survival was 72% (95% confidence interval [CI] 70-74%) in men with PSA≥100 ng/ml and M0, 24% (95% CI 23-25%) in men with PSA≥100 ng/ml and M1, and 39% (95% CI 37-40%) in men with PSA
CONCLUSIONS - One fourth of men with PSA values ≥100 ng/ml did not have distant metastases and had a 2-3 fold higher 5-year survival than men with distant metastases on imaging. Our findings strongly suggest that the use of PSA≥100 ng/ml as indicator of metastatic disease should be reconsidered.
J Urol. 2015 Jul 17. pii: S0022-5347(15)04415-8. doi: 10.1016/j.juro.2015.07.082. [Epub ahead of print]
Stattin K1, Sandin F2, Bratt O3, Lambe M4.
1 Department of Surgical Sciences, Uppsala University, Sweden.
2 Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden.
3 Urological Cancer Research Unit, Department of Translational Medicine, Lund University , Sweden; Department of Urology, Cambridge Hospitals, United Kingdom.
4 Regional Cancer Center, Uppsala University Hospital, Uppsala, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.